SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is drawing intense community interest due to the potential for regulatory tailwinds and positive sentiment surrounding the psychedelic-assisted therapy sector. Discussions are currently centered on anticipation for upcoming Phase 3 trial data, speculative interest in potential M&A activity, and active debates among traders regarding the company's long-term commercial strategy versus historical governance concerns.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crow with knife community is actively hyping the token as an essential meme-sector asset, emphasizing its deflationary burn mechanism and multichain presence. Supporters are rallying around the project's grassroots growth and organic cult following, often framing it as a lighthearted yet serious contender in the current meme coin landscape.

Highstreet

Highstreet is actively trending as the community debates its potential for a massive short squeeze following a period of extreme volatility and a sharp price decline. While some traders view the token as a high-conviction recovery play with an oversold chart, others express caution, labeling it a risky asset prone to repeated pump-and-dump cycles.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility as market participants debate whether the recent surge is driven by legitimate event-based utility or market manipulation. While supporters point to global festival partnerships and upcoming events as catalysts for growth, skeptics warn of concentrated token ownership and potential pump-and-dump mechanics amid heavy short-squeeze speculation.

Daddy Darth Sidious

SIDIOUS is gaining traction within the nano-cap meme coin community as traders speculate on a potential rotation from related tokens like MAULCOIN and DARTH. Participants are actively discussing entry points and the prospect of rapid growth, often framed around the concept of the 'Daddy Darth' thematic wars.

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in Chicago, IL.

Bright Minds Biosciences Inc

Bright Minds Biosciences is trending as investors frequently compare its potential to previous parabolic biotech runs, citing positive clinical data and strong analyst interest. The community remains focused on the possibility of a buyout or major partnership, often drawing parallels to past small-cap biotechs that saw dramatic, rapid appreciation.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin (CRO) is seeing mixed community sentiment as investors weigh persistent concerns about token dilution against potential catalysts like upcoming exchange-linked ETF filings and ongoing integration with AI-focused infrastructure. While many retail holders express frustration over the asset's lagging performance compared to major tokens, others are actively accumulating, pointing to institutional interest and potential regulatory developments as reasons for long-term optimism.

PolySwarm

PolySwarm is capturing significant community attention as traders analyze the token's cybersecurity utility against a backdrop of ongoing accumulation and low-float volatility. Investors are actively discussing the potential for a breakout, citing technical setups, whale activity, and the increasing demand for decentralized threat detection as primary drivers.

Daddy Darth Vader

Daddy Darth Vader ($DARTH) is trending as part of a highly debated "Daddy Wars" social media rivalry with other community-driven meme coins, fueled by aggressive token giveaways and community-led recruitment. Traders are actively discussing the project's low market cap, its potential as a weekend runner, and conflicting community opinions over whether the project acts as a legitimate trading vehicle or a high-risk pump and dump.

Portillo's, Inc. serves street food through high-energy, multichannel restaurants designed to ignite the senses and create a memorable dining experience. The company was founded on June 8, 2021 and is headquartered in Oak Brook, IL.

Portillos Inc - Ordinary Shares - Class A

Portillo's is trending as investors debate the potential for a rebound, highlighting strong grassroots demand at new locations in Georgia and Illinois versus concerns over leadership transition and margin compression. The community is actively discussing a potential short squeeze, recent insider activity, and the company's long-term expansion strategy as the stock trades near historical lows.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Definium Therapeutics Anxiety Drug A Multi-Billion Opportunity: Analyst

Stifel starts Definium coverage, citing strong DT120 potential in anxiety and key 2026 trial catalysts shaping outlook.read more...

Definium Therapeutics Teases 3 Phase III DT120 Readouts in 2026, Starting Late Q2 MDD Data

Definium Therapeutics (NASDAQ:DFTX) is approaching what Chief Executive Officer Rob Barrow described as an "incredibly exciting time," with pivotal data expected this year for DT120, the company's proprietary form of LSD being studied in generalized anxiety disorder (GAD) and major depressive disord...

Definium Therapeutics (NASDAQ:DFTX) Now Covered by Analysts at Piper Sandler

Piper Sandler assumed coverage on Definium Therapeutics in a report on Friday. They issued an "overweight" rating and a $49.00 price objective for the company...

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and...

Definium Therapeutics (NASDAQ:DFTX) Sets New 12-Month High  - Here's What Happened

Definium Therapeutics (NASDAQ:DFTX) Hits New 12-Month High - Here's What Happened...

Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Rating of "Buy" by Analysts

Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) has been assigned a consensus rating of "Buy" from the twelve brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and two hav...

Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week High - Here's Why

Definium Therapeutics (NASDAQ:DFTX) Hits New 52-Week High - Still a Buy...

Definium Therapeutics, Inc. (NASDAQ:DFTX) Short Interest Update

Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) was the target of a large decline in short interest in March. As of March 13th, there was short interest totaling 15,008,738 shares, a...

Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced additional details for its Investor & Analyst Day in New York on...

DFTX
Definium Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest DFTX News

DFTXDefinium Therapeutics Inc.